Recce Pharmaceuticals Ltd Stock OTC Markets
Stocks
RECEF
AU000000RCE5
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2200 USD | -56.00% |
|
-.--% | - |
| 06-25 | Recce Pharmaceuticals to Raise AU$4 million via Share Placement; Shares Down 17% | MT |
| 06-23 | Recce Pharmaceuticals Requests Trading Halt Ahead of Equity Raise | MT |
| Market Cap | 115M 80.19M 70.15M 64.7M 59.76M 113M 7.65B 773M 304M 3.77B 301M 295M 12.95B | P/E 2026 * |
-5.42x | P/E 2027 * | -3.55x |
|---|---|---|---|---|---|
| Enterprise Value | 123M 85.86M 75.1M 69.27M 63.98M 121M 8.19B 828M 325M 4.03B 322M 315M 13.87B | EV / Sales 2026 * |
16.1x | EV / Sales 2027 * | 16.8x |
| Free-Float |
60.61% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -56.00% |
| 3 years | 0.22 |  | 0.6 |
| 5 years | 0.22 | | 0.6 |
| 10 years | 0.22 | | 0.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 2020-08-27 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 2020-09-29 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 2012-09-30 |
James Graham
BRD | Director/Board Member | - | 2012-04-30 |
| Director/Board Member | - | 2022-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -56.00% | -.--% | - | - | 80.19M | |
| -2.33% | -2.09% | +49.88% | +170.51% | 1,060B | |
| -0.82% | -2.30% | +63.79% | +62.00% | 619B | |
| -0.73% | -4.98% | +28.91% | +82.99% | 438B | |
| +0.33% | -1.17% | +31.07% | +27.09% | 333B | |
| -0.02% | -2.85% | +29.15% | +45.24% | 282B | |
| -3.89% | -11.22% | +22.81% | +27.30% | 267B | |
| +0.66% | -1.42% | -26.59% | -37.71% | 218B | |
| -0.06% | -2.88% | +23.07% | +62.33% | 196B | |
| -3.72% | -1.10% | +18.41% | +70.56% | 161B | |
| Average | -6.66% | -3.25% | +26.72% | +56.70% | 397.1B | |
| Weighted average by Cap. | -1.32% | -2.96% | +36.75% | +83.91% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.68M 5.34M 4.67M 4.31M 3.98M 7.55M 509M 51.46M 20.21M 251M 20.05M 19.61M 862M | 8.86M 6.16M 5.39M 4.97M 4.59M 8.71M 588M 59.42M 23.33M 290M 23.14M 22.64M 996M |
| Net income | -20.45M -14.22M -12.44M -11.47M -10.6M -20.11M -1.36B -137M -53.84M -668M -53.4M -52.24M -2.3B | -30.9M -21.49M -18.8M -17.34M -16.02M -30.39M -2.05B -207M -81.37M -1.01B -80.7M -78.95M -3.47B |
| Net Debt | 8.15M 5.67M 4.96M 4.57M 4.22M 8.02M 541M 54.65M 21.46M 266M 21.28M 20.82M 916M | 33.53M 23.32M 20.4M 18.82M 17.38M 32.98M 2.22B 225M 88.29M 1.1B 87.57M 85.66M 3.77B |
Employees
-
Sector
Pharmaceuticals
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
- RECEF Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
